Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia

Jonathan Hoggatt, Tiffany A. Tate, Louis M. Pelus

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Chemotherapy, irradiation, and other agents are widely used to target the process of cell division in neoplastic cells. However, while these therapies are effective against most cancers, the high proliferative rate of the cells of the hematopoietic system that produce billions of blood cells needed daily throughout life is extremely sensitive to these agents, resulting in loss of blood cell populations, which can be life threatening. Neutropenia is the most serious hematologic toxicity of chemotherapy, which can result in patient morbidity and mortality due to opportunistic infection and often is the limiting factor in dose escalation or duration of chemotherapeutic administration. Neutropenic patients often require hospitalization and incur substantial medical costs associated with anti-infective therapy. Treatment of iatrogenic and congenic neutropenia was changed in the early 1990s with the introduction of filgrastim (Neupogen®) and pegfilgrastim (Neulasta®). With the expiration of patent lives of both of these drugs, biosimilars have begun to emerge. In this review, we will summarize the chemical characteristics, pharmacokinetics, safety and efficacy of lipegfilgrastim (Lonquex®), the first long-acting biosimilar filgrastim to receive regulatory approval and enter the marketplace.

Original languageEnglish (US)
Pages (from-to)2647-2652
Number of pages6
JournalInternational Journal of Nanomedicine
Volume10
DOIs
StatePublished - Apr 1 2015

Fingerprint

Biosimilar Pharmaceuticals
Chemotherapy
Neutropenia
Cells
Drug Therapy
Blood Cells
Blood
Hematopoietic System
Pharmacokinetics
Opportunistic Infections
Cell Division
Toxicity
Hospitalization
Therapeutics
Irradiation
Morbidity
Safety
Costs and Cost Analysis
Mortality
Pharmaceutical Preparations

Keywords

  • Biosimilar
  • Cancer
  • Filgrastim
  • Granulocyte-colony stimulating factor
  • Neutrophil
  • XM22

ASJC Scopus subject areas

  • Biophysics
  • Bioengineering
  • Biomaterials
  • Organic Chemistry
  • Drug Discovery

Cite this

Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia. / Hoggatt, Jonathan; Tate, Tiffany A.; Pelus, Louis M.

In: International Journal of Nanomedicine, Vol. 10, 01.04.2015, p. 2647-2652.

Research output: Contribution to journalReview article

Hoggatt, Jonathan ; Tate, Tiffany A. ; Pelus, Louis M. / Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia. In: International Journal of Nanomedicine. 2015 ; Vol. 10. pp. 2647-2652.
@article{9dfc30fb43c447269fe792cd14545717,
title = "Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia",
abstract = "Chemotherapy, irradiation, and other agents are widely used to target the process of cell division in neoplastic cells. However, while these therapies are effective against most cancers, the high proliferative rate of the cells of the hematopoietic system that produce billions of blood cells needed daily throughout life is extremely sensitive to these agents, resulting in loss of blood cell populations, which can be life threatening. Neutropenia is the most serious hematologic toxicity of chemotherapy, which can result in patient morbidity and mortality due to opportunistic infection and often is the limiting factor in dose escalation or duration of chemotherapeutic administration. Neutropenic patients often require hospitalization and incur substantial medical costs associated with anti-infective therapy. Treatment of iatrogenic and congenic neutropenia was changed in the early 1990s with the introduction of filgrastim (Neupogen{\circledR}) and pegfilgrastim (Neulasta{\circledR}). With the expiration of patent lives of both of these drugs, biosimilars have begun to emerge. In this review, we will summarize the chemical characteristics, pharmacokinetics, safety and efficacy of lipegfilgrastim (Lonquex{\circledR}), the first long-acting biosimilar filgrastim to receive regulatory approval and enter the marketplace.",
keywords = "Biosimilar, Cancer, Filgrastim, Granulocyte-colony stimulating factor, Neutrophil, XM22",
author = "Jonathan Hoggatt and Tate, {Tiffany A.} and Pelus, {Louis M.}",
year = "2015",
month = "4",
day = "1",
doi = "10.2147/IJN.S55796",
language = "English (US)",
volume = "10",
pages = "2647--2652",
journal = "International Journal of Nanomedicine",
issn = "1176-9114",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia

AU - Hoggatt, Jonathan

AU - Tate, Tiffany A.

AU - Pelus, Louis M.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Chemotherapy, irradiation, and other agents are widely used to target the process of cell division in neoplastic cells. However, while these therapies are effective against most cancers, the high proliferative rate of the cells of the hematopoietic system that produce billions of blood cells needed daily throughout life is extremely sensitive to these agents, resulting in loss of blood cell populations, which can be life threatening. Neutropenia is the most serious hematologic toxicity of chemotherapy, which can result in patient morbidity and mortality due to opportunistic infection and often is the limiting factor in dose escalation or duration of chemotherapeutic administration. Neutropenic patients often require hospitalization and incur substantial medical costs associated with anti-infective therapy. Treatment of iatrogenic and congenic neutropenia was changed in the early 1990s with the introduction of filgrastim (Neupogen®) and pegfilgrastim (Neulasta®). With the expiration of patent lives of both of these drugs, biosimilars have begun to emerge. In this review, we will summarize the chemical characteristics, pharmacokinetics, safety and efficacy of lipegfilgrastim (Lonquex®), the first long-acting biosimilar filgrastim to receive regulatory approval and enter the marketplace.

AB - Chemotherapy, irradiation, and other agents are widely used to target the process of cell division in neoplastic cells. However, while these therapies are effective against most cancers, the high proliferative rate of the cells of the hematopoietic system that produce billions of blood cells needed daily throughout life is extremely sensitive to these agents, resulting in loss of blood cell populations, which can be life threatening. Neutropenia is the most serious hematologic toxicity of chemotherapy, which can result in patient morbidity and mortality due to opportunistic infection and often is the limiting factor in dose escalation or duration of chemotherapeutic administration. Neutropenic patients often require hospitalization and incur substantial medical costs associated with anti-infective therapy. Treatment of iatrogenic and congenic neutropenia was changed in the early 1990s with the introduction of filgrastim (Neupogen®) and pegfilgrastim (Neulasta®). With the expiration of patent lives of both of these drugs, biosimilars have begun to emerge. In this review, we will summarize the chemical characteristics, pharmacokinetics, safety and efficacy of lipegfilgrastim (Lonquex®), the first long-acting biosimilar filgrastim to receive regulatory approval and enter the marketplace.

KW - Biosimilar

KW - Cancer

KW - Filgrastim

KW - Granulocyte-colony stimulating factor

KW - Neutrophil

KW - XM22

UR - http://www.scopus.com/inward/record.url?scp=84928152583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928152583&partnerID=8YFLogxK

U2 - 10.2147/IJN.S55796

DO - 10.2147/IJN.S55796

M3 - Review article

C2 - 25878498

AN - SCOPUS:84928152583

VL - 10

SP - 2647

EP - 2652

JO - International Journal of Nanomedicine

JF - International Journal of Nanomedicine

SN - 1176-9114

ER -